No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant ...

No. 2 / 2025 Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

A bill aiming to make opioid treatment programs unlawful was introduced into the West Virginia Senate last week.

Total 4Q and full year 2024 net product revenue of $118.8 million and $385.7 million, respectively, representing 66% and 88% year-over-year ...

Get real-time updates on health from celebrity fitness secrets and weight loss breakthroughs to nutrition advice, get your ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Explore the science behind why we always have room for dessert, even after a full meal, and the brain's sugar cravings.

Who hasn't been there? The big meal is over, you're full, but the craving for sweets remains. Researchers from the Max Planck ...

"I've been having pain and UTI issues since I was eight or nine. That's how long I was gaslit into believing my searing pain ...

Aristotle Atlantic’s Focus Growth Composite posted a total return of 5.05% gross of fees, underperforming the 7.07% total return of the Russell 1000 Growth Index.